Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$6.26
$5.94
$5.26
$11.38
$250.78M0.66579,804 shs336,227 shs
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$12.79
+2.0%
$13.88
$8.66
$19.14
$1.73B1.551.63 million shs1.66 million shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.15
$1.15
$0.98
$1.89
$35.95M-0.6866,043 shs26,322 shs
Cytosorbents Co. stock logo
CTSO
Cytosorbents
$0.81
+1.3%
$0.94
$0.78
$4.29
$43.98M0.58156,831 shs97,905 shs
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$9.54
$8.53
$5.48
$14.23
$354.92M1.31822,700 shs1.16 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
0.00%-0.79%+16.79%+4.51%-29.66%
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
+1.99%-2.37%-3.25%-20.06%-20.80%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-2.54%-2.54%-9.45%-20.69%
Cytosorbents Co. stock logo
CTSO
Cytosorbents
+1.00%-6.55%-8.98%-11.59%-72.73%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.7074 of 5 stars
3.54.00.04.23.23.31.3
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
3.6727 of 5 stars
3.51.00.03.30.05.00.6
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.7763 of 5 stars
3.02.00.04.40.60.00.6
Cytosorbents Co. stock logo
CTSO
Cytosorbents
1.3495 of 5 stars
3.32.00.00.03.00.00.6
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25127.64% Upside
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
3.00
Buy$23.6384.71% Upside
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50117.39% Upside
Cytosorbents Co. stock logo
CTSO
Cytosorbents
2.50
Moderate Buy$2.50208.64% Upside
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/A

Current Analyst Ratings

Latest ANGO, CTSO, SPNE, ATEC, and CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
3/28/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $23.00
3/20/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
3/20/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $22.00
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
3/15/2024
Cytosorbents Co. stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00
3/4/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
2/28/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
2/9/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$26.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$338.75M0.74$1.10 per share5.71$9.64 per share0.65
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$482.26M3.66N/AN/A$0.57 per share22.44
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.28N/AN/A$2.81 per share0.41
Cytosorbents Co. stock logo
CTSO
Cytosorbents
$36.35M1.21N/AN/A$0.52 per share1.56
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$191.45M1.85N/AN/A$8.57 per share1.11

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$186.64M-$1.55N/AN/AN/A-38.70%N/A-27.93%5/7/2024 (Confirmed)
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$28.51M-$0.64N/AN/AN/A-78.43%-120.24%-54.11%5/7/2024 (Estimated)
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
-$54.35M-$1.77N/AN/AN/A-28.22%-22.16%-17.09%N/A

Latest ANGO, CTSO, SPNE, ATEC, and CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$0.33N/A+$0.33N/AN/AN/A  
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/14/2024Q4 2023
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$0.14-$0.12+$0.02-$0.12$9.29 million$8.67 million
2/27/2024Q4 2023
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$0.28-$0.37-$0.09-$0.37$131.90 million$138.00 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Cytosorbents Co. stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
6.54
2.86
1.99
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
Cytosorbents Co. stock logo
CTSO
Cytosorbents
0.11
1.77
1.51
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.09
3.18
1.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
66.35%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Cytosorbents Co. stock logo
CTSO
Cytosorbents
32.87%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
70.81%

Insider Ownership

CompanyInsider Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
29.12%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
Cytosorbents Co. stock logo
CTSO
Cytosorbents
8.10%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
9.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
839137.98 million97.80 millionOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
Cytosorbents Co. stock logo
CTSO
Cytosorbents
18654.29 million49.90 millionOptionable
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
52337.20 million33.74 millionOptionable

ANGO, CTSO, SPNE, ATEC, and CODX Headlines

SourceHeadline
Orthofix names CLO replacement following trio of executive dismissals last yearOrthofix names CLO replacement following trio of executive dismissals last year
globallegalpost.com - April 19 at 10:32 AM
Theradaptive adds former Orthofix leader as chief scientific officerTheradaptive adds former Orthofix leader as chief scientific officer
beckersspine.com - April 16 at 6:18 PM
Orthobond Received FDA De Novo Approval for Antibacterial TechnologyOrthobond Received FDA De Novo Approval for Antibacterial Technology
jdsupra.com - April 16 at 1:18 PM
Theradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific OfficerTheradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific Officer
finance.yahoo.com - April 16 at 1:18 PM
Orthobond wins FDA de novo approval for antimicrobial technology that could have vast device applicationsOrthobond wins FDA de novo approval for antimicrobial technology that could have vast device applications
massdevice.com - April 8 at 2:26 PM
SeaSpine, Orthofix name chief enabling technologies officerSeaSpine, Orthofix name chief enabling technologies officer
beckersspine.com - April 1 at 2:54 PM
Surgeons Use Apple VR Headset During Spinal OperationSurgeons Use Apple VR Headset During Spinal Operation
futurism.com - March 18 at 8:03 AM
Lucas Vitale Joins Orthofix as Chief People and Business Operations OfficerLucas Vitale Joins Orthofix as Chief People and Business Operations Officer
stockhouse.com - March 18 at 8:03 AM
Nikki Haley says Susan Collins showed a ‘steel spine’ for backing her over Trump in GOP primaryNikki Haley says Susan Collins showed a ‘steel spine’ for backing her over Trump in GOP primary
usatoday.com - March 6 at 7:11 PM
Bone Grafts and Substitutes Market Ascends to a Robust US$6.3 Billion Valuation by 2032Bone Grafts and Substitutes Market Ascends to a Robust US$6.3 Billion Valuation by 2032
pharmiweb.com - February 5 at 2:06 AM
Spine Biologics Market Revolution: Redefining Spine Treatment ApproachesSpine Biologics Market Revolution: Redefining Spine Treatment Approaches
pharmiweb.com - December 29 at 1:03 PM
OHSU completes 1st awake spine surgeryOHSU completes 1st awake spine surgery
beckersasc.com - December 22 at 11:40 PM
Prosecutors investigate spinal implantProsecutors investigate spinal implant
bbc.com - December 20 at 12:58 AM
Medical Moment: Alternative to spinal fusion helping some patientsMedical Moment: Alternative to spinal fusion helping some patients
wndu.com - December 17 at 11:59 PM
Epidural Steroid Injections Ineffective for Lumbar Spinal StenosisEpidural Steroid Injections Ineffective for Lumbar Spinal Stenosis
medscape.com - December 16 at 6:56 PM
10 spine, orthopedic patent disputes to know10 spine, orthopedic patent disputes to know
beckersspine.com - December 15 at 7:34 PM
Polyether Ether Ketone Interbody Devices Market on the Verge of Surging to US$ 4525 Million by 2033-FMI ProjectionPolyether Ether Ketone Interbody Devices Market on the Verge of Surging to US$ 4525 Million by 2033-FMI Projection
fmiblog.com - December 7 at 10:26 AM
Orthobiologics Market size to grow by USD 2.64 billion from 2022-2027, North America to account for 41% of market growth - TechnavioOrthobiologics Market size to grow by USD 2.64 billion from 2022-2027, North America to account for 41% of market growth - Technavio
finance.yahoo.com - December 1 at 7:42 PM
How well-positioned is Orthofix for 2024?How well-positioned is Orthofix for 2024?
beckersspine.com - December 1 at 2:42 PM
Back Pain In Winter Home Remedies: Top 10 Essential Tips to Keep You Spine Healthy While SleepingBack Pain In Winter Home Remedies: Top 10 Essential Tips to Keep You Spine Healthy While Sleeping
thehealthsite.com - November 28 at 12:19 PM
Orthofix has a new CEOOrthofix has a new CEO
massdevice.com - November 28 at 12:19 PM
Virginia running back undergoes spinal surgery after leaving game on stretcherVirginia running back undergoes spinal surgery after leaving game on stretcher
foxnews.com - November 14 at 6:24 PM
Chinese scientists claim anti-ageing breakthrough with spinal cord discoveryChinese scientists claim anti-ageing breakthrough with spinal cord discovery
scmp.com - November 9 at 2:59 PM
Orthofix Reports Third Quarter 2023 ResultsOrthofix Reports Third Quarter 2023 Results
finance.yahoo.com - November 8 at 7:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Alphatec logo

Alphatec

NASDAQ:ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Cytosorbents logo

Cytosorbents

NASDAQ:CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
SeaSpine logo

SeaSpine

NASDAQ:SPNE
As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.